Integrin alphaVbeta3 targeted gene delivery using RGD peptidomimetic conjugates with copolymers of PEGylated poly(ethylene imine).

This study describes the synthesis and characterization of five conjugates of poly(ethylene glycol) modified polyethylenimine (PEG-PEIs) coupled in two different synthesis routes to a nonpeptidic pentacyclic RDG-mimetic for integrin receptor-targeted gene delivery. Synthesis of this panel of different conjugates allowed for systematic analysis of structure-activity relationships. Conjugates were therefore characterized regarding molecular composition, DNA condensation, size, and zeta potential of self-assembled polyplexes. In vitro characterization included investigation of blood compatibility, binding affinity to receptor-positive and receptor-negative cells measured by flow cytometry, cellular uptake quantified by scintillation counting, and efficiency and specificity of transfection assayed by reporter gene expression. In a first synthetic approach, low molecular weight PEI (LMW-PEI) was PEGylated using a heterobifunctional PEG linker and coupling of the RGD-mimetic was achieved at the distal end of PEG chains. In a second synthesis route, the RGD-mimetic was directly coupled to AB-block-copolymers of PEI (25 kDa) and PEG (30 kDa). Interactions of RGD-PEG-LMW-PEI conjugates with DNA were strongly impaired, whereas PEG-PEI-RGD conjugates were more promising candidates due to their physicochemical properties and higher receptor specificity. The binding, uptake, and transfection efficiency in receptor-positive cells was strongly increased upon conjugation of the RGD-mimetic to AB-block-copolymers of PEG-PEI and depended on the degree of peptide substitution. The conjugates of PEG-PEI AB-block-copolymers with low ligand density of the RGD-mimetic appear to be promising candidates for in vivo cancer gene therapy.

[1]  R. Juliano,et al.  Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. , 2008, Bioconjugate chemistry.

[2]  I. Pastan,et al.  Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. , 1980, The Journal of biological chemistry.

[3]  M. Ishikawa,et al.  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 2: Synthesis of potent αvβ3/αIIbβ3 dual antagonists , 2006 .

[4]  L. Campisi,et al.  Vitronectin receptor antibodies inhibit infection of HeLa and A549 cells by adenovirus type 12 but not by adenovirus type 2 , 1994, Journal of virology.

[5]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Yu Matsumoto,et al.  Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. , 2008, Molecular pharmaceutics.

[7]  B. Clotet,et al.  Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. , 2009, Blood.

[8]  H. Gresham,et al.  Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins , 1990, The Journal of cell biology.

[9]  J. Xie,et al.  Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor. , 2005, Bioorganic & medicinal chemistry.

[10]  E. Kokkoli,et al.  PR_b-targeted PEGylated liposomes for prostate cancer therapy. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[11]  T. Kissel,et al.  HER2 targeted polyplexes: the effect of polyplex composition and conjugation chemistry on in vitro and in vivo characteristics. , 2008, Bioconjugate chemistry.

[12]  J. Kopeček,et al.  Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. , 2003, Bioconjugate chemistry.

[13]  T. Kissel,et al.  Integrin targeting using RGD‐PEI conjugates for in vitro gene transfer , 2003, The journal of gene medicine.

[14]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[15]  R. Schiffelers,et al.  ICS-283: a system for targeted intravenous delivery of siRNA , 2006, Expert opinion on drug delivery.

[16]  R. Mahato,et al.  Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives , 1997, Pharmaceutical Research.

[17]  U. Bakowsky,et al.  Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. , 2006, Bioconjugate chemistry.

[18]  S. Carotta,et al.  DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression , 2001, AAPS PharmSci.

[19]  Susan X. Hsiong,et al.  Quantifying the relation between bond number and myoblast proliferation. , 2008, Faraday discussions.

[20]  D. Fischer,et al.  A Novel Non-Viral Vector for DNA Delivery Based on Low Molecular Weight, Branched Polyethylenimine: Effect of Molecular Weight on Transfection Efficiency and Cytotoxicity , 1999, Pharmaceutical Research.

[21]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[22]  J. Takagi Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins. , 2004, Biochemical Society transactions.

[23]  M. Ogris,et al.  PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery , 1999, Gene Therapy.

[24]  Alfons Verbruggen,et al.  Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. , 2008, Cardiovascular research.

[25]  G. Robillard,et al.  Adhesion receptors mediate efficient non-viral gene delivery. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  D. Fischer,et al.  Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Jindrich Kopecek,et al.  Intracellular Processing of Poly(Ethylene Imine)/Ribozyme Complexes Can Be Observed in Living Cells by Using Confocal Laser Scanning Microscopy and Inhibitor Experiments , 2002, Pharmaceutical Research.

[28]  S. Snyder,et al.  An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. , 1975, Analytical biochemistry.

[29]  R. Schiffelers,et al.  Transporting silence: design of carriers for siRNA to angiogenic endothelium. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[30]  G. De Rosa,et al.  Spectrophotometric determination of polyethylenimine in the presence of an oligonucleotide for the characterization of controlled release formulations. , 2003, Journal of pharmaceutical and biomedical analysis.

[31]  S. Fukushima,et al.  Cyclic RGD Peptide-Conjugated Polyplex Micelles as a Targetable Gene Delivery System Directed to Cells Possessing αvβ3 and αvβ5 Integrins , 2007 .

[32]  S. Mousa,et al.  Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. , 1999, Anticancer research.

[33]  R. Schiffelers,et al.  RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[34]  Seungpyo Hong,et al.  Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. , 2006, Bioconjugate chemistry.

[35]  D. Fischer,et al.  Synthesis, Characterization, and Biocompatibility of Polyethylenimine-graft-poly(ethylene glycol) Block Copolymers , 2002 .

[36]  T. Kissel,et al.  Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. , 2006, Bioconjugate chemistry.

[37]  Ashish Garg,et al.  Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. , 2009, International journal of pharmaceutics.

[38]  Kairbaan Hodivala-Dilke,et al.  alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. , 2008, Current opinion in cell biology.

[39]  Clive J Roberts,et al.  Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. , 2002, Bioconjugate chemistry.

[40]  D. Cheresh,et al.  Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin alpha v beta 3 and its ligand. , 1991, The Journal of biological chemistry.

[41]  M. Buchberger,et al.  Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery , 1997, Gene Therapy.

[42]  S. W. Kim,et al.  Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[43]  Andrés J. García,et al.  Simple application of fibronectin–mimetic coating enhances osseointegration of titanium implants , 2009, Journal of cellular and molecular medicine.

[44]  F. Mitjans,et al.  In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. , 2000, International journal of cancer.

[45]  K. Braeckmans,et al.  Studying the intracellular dissociation of polymer-oligonucleotide complexes by dual color fluorescence fluctuation spectroscopy and confocal imaging. , 2005, Biochemistry.

[46]  G. Molema,et al.  Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[47]  A. Kling,et al.  Highly potent and selective αVβ3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones , 2003 .